Cytotoxicity mediation of cells evidencing surface expression of CD44
US8017117B2 · kind B2 · utility
1Cited by
23References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2008 |
| Grant date | Sep 13, 2011 |
| Priority date | — |
| Expiry date | Jul 1, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70585
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.